Asset / Drug

pembrolizumab

Drug and asset intelligence for pembrolizumab with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Merck →

Mechanism of action

Immunotherapy

Recent signals(4)

ClinicalJune 21, 2026

Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy

Alnylam Pharmaceuticals is conducting a study to evaluate the safety and antitumor activity of ALN-BCAT, both alone and in combination with pembrolizumab, in patients with hepatocellular carcinoma.

ClinicalJune 18, 2026

Phase III Trial Evaluates Pembrolizumab Timing in NSCLC Treatment

A phase III trial is comparing the efficacy of pembrolizumab alone versus in combination with chemotherapy as first-line treatment for stage IV non-squamous non-small cell lung cancer.

ClinicalJune 18, 2026

Phase III Trial of Pembrolizumab Plus Doxorubicin in Aggressive Sarcomas

A phase III trial is comparing immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) against chemotherapy alone in patients with metastatic or unresectable poorly differentiated sarcomas.

ClinicalJune 17, 2026

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

The ALCHEMIST trial is evaluating the efficacy of adding pembrolizumab to standard chemotherapy in resected non-small cell lung cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Hepatocellular Carcinoma →

Therapeutic areas

Hepatocellular Carcinoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.